Streetbeat News

Price Targets

HOLX

Analyst ratings for Hologic (NASDAQ:HOLX) show mixed sentiments with a recent shift towards bullishness. The average 12-month price target is now $80.5, down from $83.50. Analysts from Needham, UBS, Morgan Stanley, and RBC Capital have adjusted their ratings and price targets, reflecting changes in market dynamics and Hologic's performance. Hologic, focusing on women's healthcare, faces challenges in market capitalization, revenue growth, net margin, ROE, ROA, and debt management compared to industry averages.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 12:00 pm

M

Analyst ratings for Macy's (NYSE:M) over the last quarter show varied opinions, with recent updates indicating a mix of neutral to bullish stances. The average 12-month price target for Macy's has been raised to $15.8, reflecting a 7.7% increase from the previous target. Financial indicators suggest Macy's faces challenges in market capitalization, revenue growth, net margin, ROE, and ROA, but has a relatively healthy debt-to-equity ratio. The company operates a significant retail and e-commerce presence, with a focus on women's apparel and beauty products.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 12:00 pm

COLL

Needham analyst Serge Belanger has reiterated a Buy rating on Collegium Pharmaceutical (NASDAQ:COLL) and maintained a $40 price target.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 11:57 am

AXON

Needham analyst Joshua Reilly has reiterated a Buy rating on Axon Enterprise (NASDAQ:AXON) and maintained a $240 price target.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 11:54 am

NYCB

Deutsche Bank analyst Bernard von-Gizycki downgraded New York Community (NYSE:NYCB) from Buy to Hold and reduced the price target from $15 to $7.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 11:51 am

TSCO

Raymond James analyst Matthew McClintock downgraded Tractor Supply (TSCO) from Strong Buy to Outperform while raising the price target from $230 to $250.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 11:45 am

TECH

Stifel analyst Daniel Arias downgraded Bio-Techne (NASDAQ:TECH) from Buy to Hold and set a new price target of $65.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 11:41 am

WEC

JP Morgan analyst Jeremy Tonet downgraded WEC Energy Group (WEC) from Neutral to Underweight and reduced the price target from $90 to $84.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 11:33 am

GFI

BMO Capital analyst Andrew Kaip downgraded Gold Fields (NYSE:GFI) from Market Perform to Underperform and reduced the price target from $14 to $12.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 11:31 am

CTVA

Exane BNP Paribas analyst Laurent Favre upgrades Corteva (NYSE:CTVA) from Underperform to Neutral and sets a $53 price target.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 11:18 am